Medexus Pharmaceuticals Inc (OTCPK:MEDXF)
$ 1.509 0.124 (8.95%) Market Cap: 37.62 Mil Enterprise Value: 72.91 Mil PE Ratio: 30.18 PB Ratio: 1.17 GF Score: 69/100

Medexus Pharmaceuticals Inc to Discuss Treosulfan Data Transcript

Jun 06, 2022 / 08:00PM GMT
Release Date Price: $1.73 (+4.04%)
Victoria Rutherford

Okay. Hello, everyone. Thank you for joining the Medexus webcast this afternoon. Today, we are joined by Filippo Milano, a physician and scientist, whose research is focused on the use of umbilical cord blood as a source of stem cells for transplantation to treat various blood cancers. He is an associate professor in the Clinical Research Division at Fred Hutch and also a Director on the Cord Blood Transplant Program in the Clinical Research Division at Fred Hutch.

Just a reminder for everyone, if I could please refer you to the forward-looking disclaimer in the press release Medexus issued this morning titled Treosulfan Pivotal Study Results Published. And with that, I'm going to turn it over to Filippo. At the end, we'll be back and we can answer a Q&A. Thanks, Filippo. Over to you.

Filippo Milano

Thank you, Victoria, and thank you, everyone, for the opportunity to be here with you and actually sharing some exciting news that have been recently released. One thing that I would like to add in terms of my area of expertise, yes, I'm the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot